Bilal Arif
Chief Tech/Sci/R&D Officer chez SAREPTA THERAPEUTICS, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Bilal Arif is currently the Chief Technical Operations Officer & Executive VP at Sarepta Therapeutics, Inc. Previously, he worked as the Vice President-Technical Operations at Momenta Pharmaceuticals, Inc. from 2017 to 2019.
Mr. Arif completed his undergraduate degree at McGill University, his graduate degree at Tufts University, and his MBA at Instituto de Empresa SL.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/03/2024 | 25 222 ( 0,03% ) | 3 M $ | 31/03/2024 |
Postes actifs de Bilal Arif
| Sociétés | Poste | Début |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2022 |
Anciens postes connus de Bilal Arif
| Sociétés | Poste | Fin |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/01/2019 |
Formation de Bilal Arif
| McGill University | Undergraduate Degree |
| Tufts University | Graduate Degree |
| Instituto de Empresa SL | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
